NCT03043677View on ClinicalTrials.gov

Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

May 30, 2018

Conditions
Inflammatory Bowel Disease
Interventions
BIOLOGICAL

Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab

"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."

All Listed Sponsors
lead

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

NCT03043677 - Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells | Biotech Hunter | Biotech Hunter